Pharmaceutical company · MKGAY

Merck KGaA
clinical trial
pipeline

Registry checked

Published

Oncology is the largest mapped primary therapeutic group, with 16 of 28 active trials. This ranking covers mapped groups only. Enpatoran is linked to 4 distinct active studies, with 1 Phase 2, 3 Phase 3. Precemtabart Tocentecan is linked to 4 distinct active studies, with 2 Phase 1, 1 Phase 2, 1 Phase 3.

Phase 3 study NCT03815643 in Solid Tumors lists estimated primary completion on 24 November 2026. Phase 2 study NCT07170644 in Desmoid Tumor and Aggressive Fibromatosis lists estimated primary completion on 28 May 2027. These are registry estimates of primary completion, not confirmed results announcements or overall study completion.

Active trial mix

Lead-sponsor scope

28active trials
as lead sponsor
  • Phase 111
  • Phase 27
  • Phase 37
  • Phase 41
  • Phase not recorded2

One highest explicitly recorded phase per active trial. Combined phases use the highest phase. Phase not recorded is shown separately.

Change history

Follow the changes behind the company’s clinical programme.

01 Oct 2026 – 30 Oct 2026 · UTC

Recorded changes

54 trials30 completed days
Recruitment statusPrimary completionEnrolmentFirst observedOther

Highlighted changes 03

Select an example to see what changed

01Primary completion

Primary completion moved earlier by 279 days

2028-07-05 (estimated)2027-09-30 (estimated)
05 Jul 202830 Sept 2027

A Study to Compare the Efficacy and Safety of Follitropin Alfa/Lutropin Alfa Versus hMG in Japanese Participants With LH and FSH Deficiency Undergoing ART (HINATA)

NCT07340827 · ClinicalTrials.gov
Recorded by ComplyRx
30 Oct 2026
Registry last updated
29 Oct 2026

Verified live registry-derived observations in completed UTC days. Recorded dates are observation dates, not necessarily registry amendment dates. Zero means no eligible observations recorded, not daily monitoring of every trial.

0 archive observations and 0 unverified observations excluded.

View exact daily values and type totals
Recorded observations in completed UTC days
Date (UTC)Recruitment statusPrimary completionEnrolmentFirst observedOtherTotalAffected trials
2026-10-010000000
2026-10-020000000
2026-10-030000000
2026-10-040000000
2026-10-050000000
2026-10-060000000
2026-10-070000000
2026-10-080000000
2026-10-091000011
2026-10-100000000
2026-10-110000000
2026-10-120000000
2026-10-130000000
2026-10-140000000
2026-10-150000000
2026-10-160000000
2026-10-170000000
2026-10-180000000
2026-10-190000000
2026-10-201100021
2026-10-210000000
2026-10-220000000
2026-10-230100011
2026-10-240000000
2026-10-250000000
2026-10-260000000
2026-10-270000000
2026-10-280000000
2026-10-290000000
2026-10-300100011
Type totals2300054 distinct

02 / Drugs & programmes

Explore the pipeline

6 selected programmes

Choose a drug to open its record in the tracker. Sign in to continue.

Enpatoran

Canonical investigational asset

4
Active trials
2
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 10
  • Phase 21
  • Phase 33
  • Phase 40
  • Phase not recorded0
Studied condition
Cutaneous Lupus Erythematosus · Cutaneous Lupus Erythematosus (CLE) · Systematic Lupus Erythematosus
Next primary completion
Not reported
Open drug

Precemtabart Tocentecan

Canonical investigational asset

4
Active trials
1
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 12
  • Phase 21
  • Phase 31
  • Phase 40
  • Phase not recorded0
Studied condition
Colorectal Cancer · Gastric Cancer · Metastatic Colorectal Cancer
Next primary completion
Not reported
Open drug

Mirdametinib

GOMEKLI

4
Active trials
2
Recruiting trials
Trial phases
Highest: Phase 2
  • Phase 13
  • Phase 21
  • Phase 30
  • Phase 40
  • Phase not recorded0
Studied condition
Healthy · Hepatic Impairment · Neurofibromatosis Type 1 (NF1)
Next primary completion
Not reported
Open drug

Nirogacestat

ogsiveo

2
Active trials
1
Recruiting trials
Trial phases
Highest: Phase 4
  • Phase 10
  • Phase 21
  • Phase 30
  • Phase 41
  • Phase not recorded0
Studied condition
Aggressive Fibromatosis · Desmoid Tumor
Next primary completion
28 May 2027 · estimated
Open drug

Avelumab

bavencio

2
Active trials
0
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 10
  • Phase 21
  • Phase 31
  • Phase 40
  • Phase not recorded0
Studied condition
Locally Advanced or Metastatic Urothelial Carcinoma · Solid Tumors
Next primary completion
24 November 2026 · estimated
Open drug

Cetrorelix

CETROTIDE

1
Active trials
1
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 10
  • Phase 20
  • Phase 31
  • Phase 40
  • Phase not recorded0
Studied condition
Infertility
Next primary completion
30 September 2027 · estimated
Open drug

26 of 28 active trials have accepted investigational programme links. Trial context does not establish ownership or complete drug coverage.

6 selected programmes · accepted investigational links cover 26 of 28 active trials · brand names checked where available.

Accepted links do not establish complete intervention mapping or ownership. Programme populations overlap.

Up to six canonical assets identified through accepted investigational links in active trials. Counts describe this trial context and do not establish ownership or a complete corporate drug portfolio. Opening a record requires sign-in and does not start tracking.

03 / Clinical trial timeline

Merck KGaA trials in progress

Registry start → study completion

◇ Recorded observation│ Primary completion milestoneHatched ends retain month / year uncertaintyHover, focus or tap an observation
Trial / programme
6 selected Phase 3 / 2 trials
2021202220232024202520262027202820292030
Avelumab Program Rollover Study
Avelumab

NCT03815643

Phase 3 · Active, not recruiting

Trial source and qualifications

Avelumab Program Rollover Study

Duration ends at independently recorded study completion. Source date qualifications: start-clipped-at-horizon. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 3 inspected observations were not displayed.

Start clipped at the display horizon.

4 candidate observations · 1 shown · 0 recorded after primary completion · 3 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

ClinicalTrials.gov source

3 inspected observations omitted. At most three verified observations are shown, not full history.

  • pc date moved · Recorded 2026-09-22 · Verified live registry-derived observation. Recorded date is not necessarily the registry amendment date. Observations outside the duration bar do not extend the study.

Start: 22 Mar 2019 · actual
Primary completion: 24 Nov 2026 · estimated
Study completion: 24 Nov 2026 · estimated

2021202220232024202520262027202820292030
A Study of Nirogacestat in Japanese Adults With Desmoid Tumors/Aggressive Fibromatosis (DT/AF)
Nirogacestat

NCT07170644

Phase 2 · Active, not recruiting

Trial source and qualifications

A Study of Nirogacestat in Japanese Adults With Desmoid Tumors/Aggressive Fibromatosis (DT/AF)

Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 4 inspected observations were not displayed.

4 candidate observations · 0 shown · 0 recorded after primary completion · 4 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

ClinicalTrials.gov source

4 inspected observations omitted. At most three verified observations are shown, not full history.

    Start: 08 Aug 2025 · actual
    Primary completion: 28 May 2027 · estimated
    Study completion: 09 Oct 2029 · estimated

    2021202220232024202520262027202820292030
    A Study to Compare the Efficacy and Safety of Follitropin Alfa/Lutropin Alfa Versus hMG in Japanese Participants With LH and FSH Deficiency Undergoing ART (HINATA)
    Cetrorelix

    NCT07340827

    Phase 3 · Recruiting

    Trial source and qualifications

    A Study to Compare the Efficacy and Safety of Follitropin Alfa/Lutropin Alfa Versus hMG in Japanese Participants With LH and FSH Deficiency Undergoing ART (HINATA)

    Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 3 inspected observations were not displayed.

    4 candidate observations · 1 shown · 0 recorded after primary completion · 3 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

    ClinicalTrials.gov source

    3 inspected observations omitted. At most three verified observations are shown, not full history.

    • pc date moved · Recorded 2026-10-30 · Verified live registry-derived observation. Recorded date is not necessarily the registry amendment date. Observations outside the duration bar do not extend the study.

    Start: 05 Feb 2026 · actual
    Primary completion: 30 Sept 2027 · estimated
    Study completion: 30 Sept 2027 · estimated

    2021202220232024202520262027202820292030
    Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)
    Precemtabart Tocentecan

    NCT06710132

    Phase 2 · Active, not recruiting

    Trial source and qualifications

    Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)

    Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 4 inspected observations were not displayed.

    5 candidate observations · 1 shown · 0 recorded after primary completion · 4 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

    ClinicalTrials.gov source

    4 inspected observations omitted. At most three verified observations are shown, not full history.

    • enrollment change · Recorded 2026-07-31 · Verified live registry-derived observation. Recorded date is not necessarily the registry amendment date. Observations outside the duration bar do not extend the study.

    Start: 29 Jan 2025 · actual
    Primary completion: 23 Dec 2027 · estimated
    Study completion: 23 Dec 2027 · estimated

    2021202220232024202520262027202820292030
    The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE (WILLOW LTE)
    Enpatoran

    NCT05540327

    Phase 2 · Active, not recruiting

    Trial source and qualifications

    The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE (WILLOW LTE)

    Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 3 inspected observations were not displayed.

    3 candidate observations · 0 shown · 0 recorded after primary completion · 3 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

    ClinicalTrials.gov source

    3 inspected observations omitted. At most three verified observations are shown, not full history.

      Start: 16 Sept 2022 · actual
      Primary completion: 12 Aug 2028 · estimated
      Study completion: 12 Aug 2028 · estimated

      2021202220232024202520262027202820292030
      Study of Pimicotinib in Japanese Participants With Tenosynovial Giant Cell Tumor (TGCT) (J-MANEUVER)
      Pimicotinib

      NCT07499362

      Phase 2 · Recruiting

      Trial source and qualifications

      Study of Pimicotinib in Japanese Participants With Tenosynovial Giant Cell Tumor (TGCT) (J-MANEUVER)

      Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 1 inspected observations were not displayed.

      2 candidate observations · 1 shown · 0 recorded after primary completion · 1 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

      ClinicalTrials.gov source

      1 inspected observations omitted. At most three verified observations are shown, not full history.

      • pc date moved · Recorded 2026-10-23 · Verified live registry-derived observation. Recorded date is not necessarily the registry amendment date. Observations outside the duration bar do not extend the study.

      Start: 26 Mar 2026 · actual
      Primary completion: 22 Aug 2028 · estimated
      Study completion: 22 Aug 2028 · estimated

      2021202220232024202520262027202820292030

      Up to six active Phase 2/3 trials with upcoming estimated primary-completion intervals, ordered by nearest interval, highest phase and NCT. Historical dates never pad this selection. Ten calendar years are shown. Dates retain registry precision and independent date types.

      6 selected of 10 eligible trials · 0 without supported dates · 0 omitted for contradictory chronology. Excluded: 3 actual primary completions, 0 untyped primary completions, 0 past estimates, 1 outside the horizon, 0 contradictory dates.

      04 / Therapeutic focus

      Where the activity is

      16

      active trials in Oncology

      Primary therapeutic groups are indexed enrichment. Unmapped trials and healthy volunteers remain in the active-trial denominator.

      Active trials by primary therapeutic area

      • Oncology16 trials
      • Immunology & Inflammation4 trials
      • Neurology3 trials
      • Gastroenterology & Hepatology1 trials
      • Womens Health1 trials
      • Unmapped2 trials
      • Healthy volunteers1 trials

      Each active trial counts once. Full bar equals all active trials in this lead-sponsor scope. This grouping does not describe commercial strategy.

      06 / Related companies

      All companies
      P

      Pfizer

      Shared indexed programme context · 3 selected assets

      A

      AbbVie

      Shared indexed programme context · 1 selected asset

      Based on the selected programmes and indexed lead-sponsor records, not a complete ranking or a competitive/ownership assessment.

      Sources, scope and methodology

      ClinicalTrials.gov lead-sponsor scope

      Canonical current-owner attribution covers 522 distinct NCT records attributed through the canonical sponsor map. Included canonical entities: Merck KGaA. Phrases retrieve candidates only, then verbatim lead-sponsor attribution determines inclusion.

      ClinicalTrials.gov

      Attribution coverage

      522 distinct registry candidates produced 522 accepted studies. 0 mapped to other owners, 0 lacked a canonical mapping and 0 fell outside an operating subset. Accepted mappings include 0 unverified, 0 identity-only and 0 device-tagged trial memberships. Mapping flags describe evidence quality, not a separate ownership authority.

      Indexed enrichment

      408 scoped records have indexed enrichment and 114 do not. Missing enrichment does not remove a trial from cohort counts.

      Scope observation

      The successful attribution check completed at 2026-10-31T19:46:27.956Z. This is a dated canonical-attribution snapshot. Static pages normally regenerate after 24 hours, but cached HTML can outlive that interval when regeneration fails. Map changes affect the next successful regeneration. This timestamp is separate from individual registry-update dates. Snapshot 174eaffb40293065c06ae0f67205cbcce93f0ac2eb21d1109bf0e5781bedb9df.

      Active means recruiting, not yet recruiting, active not recruiting or enrolling by invitation. Recruiting counts recruiting only. Trial counts describe lead sponsorship under the published canonical-attribution policy. Identified programmes and therapeutic groups depend on available enrichment. Drug, device and other clinical studies may be included. This is the mapped company scope, not an exhaustive corporate trial census.

      Dated canonical-attribution snapshot: 522 mapped lead-sponsored clinical studies across all statuses. 408 have indexed enrichment, 114 do not. Drug, device and other studies may be represented. Sponsor tags do not classify trial interventions. This is the mapped company scope, not an exhaustive corporate trial census. Recorded changes may reflect observation or archive ingestion rather than a new registry amendment.

      Keep following
      what matters.

      Choose the drugs, companies or disease areas you follow. Bring trial changes and upcoming readouts into one watch.

      Build your watch

      Choose what to track in the watch builder.